Epigallocatechin-3-gallate inhibits TF and TNF-α expression induced by the anti-β 2 GPI / β 2 GPI complex in human THP-1 cells

Epigallocatechin-3-gallate (EGCG) is the major polyphenolic component of green tea. The aim of the current study was to investigate the inhibitory effects of EGCG on antiβ2-glycoprotein I (β2GPI)/β2GPI-induced tissue factor (TF) and tumor necrosis factor-α (TNF-α) expression in the human acute monocytic leukemia cell line, THP-1, as well as the underlying mechanisms. Human THP-1 cells cultured in vitro were treated with lipopolysaccharide (LPS, 500 ng/ml) or with the anti-β2GPI (10 μg/ml)/β2GPI (100 μg/ml) complex following pre-treatment with or without EGCG (0-50 μg/ml). The expression levels of TF, TNF-α and Toll-like receptor 4 (TLR4) were measured, and the activation of mitogen-activated protein kinases (MAPKs) including p38, extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), and the nuclear factor-κB (NF-κB) signaling pathway was determined by western blot analysis. The results revealed that the anti-β2GPI/β2GPI complex activated the THP-1 cells, resulting in the enhanced expression of the coagulation cytokine, TF, as well as that of the pro-inflammatory cytokine, TNF-α; these levels were almost comparable to those induced by LPS. Pre-treatment with EGCG decreased the TF and TNF-α levels in the THP-1 cells treated with the anti-β2GPI/β2GPI complex in a dose-dependent manner and counteracted the upregulation of TLR4 expression (mRNA and protein) which was induced by the anti-β2GPI/β2GPI complex or LPS. Furthermore, EGCG suppressed the phosphorylation of p38, ERK1/2 and JNK and blocked the activation of the NF-κB signaling pathway induced by the anti-β2GPI/β2GPI complex or LPS. In conclusion, our results indicate that EGCG decreases the anti-β2GPI/β2GPIinduced TF and TNF-α expression in THP-1 cells possibly through the inhibition of the intracellular signal transduction pathway of TLRs-MAPKs-NF-κB axis and may serve as a preventive and therapeutic agent for antiphospholipid syndrome (APS).

[1]  S. H. Lee,et al.  Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. , 2013, European journal of cancer.

[2]  Xue-Jun Song,et al.  WNT signaling underlies the pathogenesis of neuropathic pain in rodents. , 2013, The Journal of clinical investigation.

[3]  Hong Zhou,et al.  Both NF-κB and c-Jun/AP-1 involved in anti-β2GPI/β2GPI-induced tissue factor expression in monocytes , 2013, Thrombosis and Haemostasis.

[4]  Hong Zhou,et al.  Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. , 2013, Molecular immunology.

[5]  Hong Zhou,et al.  Activation of MAPKs in the anti-β2GPI/β2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. , 2012, Thrombosis research.

[6]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[7]  M. Khamashta,et al.  Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome , 2012, Seminars in Thrombosis & Hemostasis.

[8]  Hui-Yi Lin,et al.  (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. , 2012, Journal of agricultural and food chemistry.

[9]  Hong Zhou,et al.  Involvement of IRAKs and TRAFs in anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells , 2011, Thrombosis and Haemostasis.

[10]  G. Espinosa,et al.  Management of refractory cases of catastrophic antiphospholipid syndrome. , 2011, Autoimmunity reviews.

[11]  J. Musial,et al.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state , 2011, Rheumatology International.

[12]  M. Petri Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients , 2011, Current rheumatology reports.

[13]  H. Zhou,et al.  Toll‐like receptor (TLR)‐4 mediates anti‐β2GPI/β2GPI‐induced tissue factor expression in THP‐1 cells , 2011, Clinical and experimental immunology.

[14]  Zhiwei Wang,et al.  The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer , 2010, Cancer and Metastasis Reviews.

[15]  A. Akhmedov,et al.  Laminin receptor activation inhibits endothelial tissue factor expression. , 2010, Journal of molecular and cellular cardiology.

[16]  O. Neth,et al.  Infant With Probable Catastrophic Antiphospholipid Syndrome Successfully Managed With Rituximab , 2010, Pediatrics.

[17]  M. Khamashta,et al.  Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future , 2010, European journal of clinical investigation.

[18]  N. Mackman,et al.  Role of tissue factor in thrombosis in antiphospholipid antibody syndrome , 2010, Lupus.

[19]  Hong Zhou,et al.  Annexin A2 mediates anti-β2GPI/β2GPI-induced tissue factor expression on monocytes , 2009 .

[20]  J. Brosens,et al.  ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Pro‐Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway , 2009, American journal of reproductive immunology.

[21]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[22]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[23]  Chunli Shao,et al.  The roles of MAPKs in disease , 2008, Cell Research.

[24]  J. Um,et al.  Epigallocatechin-3-gallate suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells , 2007 .

[25]  E. García-Latorre,et al.  In Vivo Effects of an Inhibitor of Nuclear Factor‐Kappa B on Thrombogenic Properties of Antiphospholipid Antibodies , 2007, Annals of the New York Academy of Sciences.

[26]  Xiaowei Liu,et al.  Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies , 2007, Annals of the rheumatic diseases.

[27]  K. Kang,et al.  Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea. , 2006, Biochemical pharmacology.

[28]  M. Goodrick,et al.  Antiphospholipid syndrome: a series of surgical emergencies and the current evidence for its management. , 2006, Annals of the Royal College of Surgeons of England.

[29]  M. Martinuzzo,et al.  Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies , 2005, Lupus.

[30]  A. Wolberg,et al.  Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. , 2004, Blood.

[31]  P. D. de Groot,et al.  beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. , 2004, Clinical immunology.

[32]  P. D. de Groot,et al.  Antiphospholipid antibodies: update on detection, pathophysiology, and treatment , 2004, Current opinion in hematology.

[33]  W. Faulk,et al.  Antiphospholipid antibodies: discovery, definitions, detection and disease. , 2003, Progress in lipid research.

[34]  K. Yoon Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndome. , 2002, The Journal of rheumatology.

[35]  A. Gharavi,et al.  GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. , 1999, Journal of immunology.

[36]  Xiaowei Liu,et al.  Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. , 1999, Circulation.

[37]  J. Barker,et al.  Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. , 1996, Circulation.

[38]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[39]  J. Um,et al.  Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. , 2007, International archives of allergy and immunology.

[40]  Y. Oh,et al.  Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. , 2004, Biochemical and biophysical research communications.

[41]  V. Malhotra,et al.  Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. , 2004, The Journal of nutrition.

[42]  H. Fujiki,et al.  Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-α expression , 2000 .

[43]  Y. L. Lin,et al.  (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. , 1997, Molecular pharmacology.